Vivus
INVADrugs in Pipeline
6
Phase 3 Programs
2
Upcoming Catalysts
2
Next Catalyst
Aug 5, 2026
26dMarket Overview
Stock performance and key metrics
3 upcoming, 0 past
How INVA's past catalysts played out
VI-0521
Obesity
avanafil
Erectile Dysfunction
VI-1121
Alzheimer's Disease
Phentermine/Topiramate
Diabetes
Topical alprostadil (PGE-1)
Sexual Dysfunction, Physiological
VI-0609
Lymphoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
VI-0521 | Phase 3 | Obesity | - | - |
avanafil | Phase 3 | Erectile Dysfunction | - | - |
VI-1121 | Phase 2 | Alzheimer's Disease | - | - |
Phentermine/Topiramate | Phase 2 | Diabetes | - | - |
Topical alprostadil (PGE-1) | Phase 2 | Sexual Dysfunction, Physiological | - | - |
VI-0609 | Phase 2 | Lymphoma | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Vivus's drug pipeline?→
CatalystAlert tracks 6 drug candidates in Vivus's (INVA) pipeline across Phase 3, Phase 2. Its lead program is VI-0521 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Vivus's next FDA catalyst?→
Vivus's (INVA) next tracked catalyst is a Earnings expected August 5, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track INVA biotech catalysts?→
Add INVA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Vivus's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.